A5046555824- Cancer Genomics and Diagnostics
- Advanced Breast Cancer Therapies
- Breast Cancer Treatment Studies
- Lung Cancer Treatments and Mutations
- Cancer Diagnosis and Treatment
- Cancer survivorship and care
- Cancer Treatment and Pharmacology
- HER2/EGFR in Cancer Research
- Management of metastatic bone disease
- Bone health and treatments
- Breast Implant and Reconstruction
- Colorectal Cancer Treatments and Studies
- Estrogen and related hormone effects
- Cancer Risks and Factors
- Cancer-related molecular mechanisms research
- Brain Metastases and Treatment
- Economic and Financial Impacts of Cancer
- Immune cells in cancer
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Intestinal and Peritoneal Adhesions
- BRCA gene mutations in cancer
- Oral and Maxillofacial Pathology
- Breast Lesions and Carcinomas
- Inflammation biomarkers and pathways
- Bone and Joint Diseases
Ente Ospedaliero Cantonale
2020-2024
Dana-Farber Cancer Institute
2018-2023
Institute of Oncology Research
2014-2023
Broad Institute
2019-2023
Harvard University
2018-2021
Brigham and Women's Hospital
2018-2019
University of Colorado Cancer Center
2018
University of Colorado Denver
2018
Dana-Farber Brigham Cancer Center
2018
Stanford University
2018
Importance Data on oncological outcomes after omission of axillary lymph node dissection (ALND) in patients with breast cancer that downstages from positive to negative neoadjuvant chemotherapy are sparse. Additionally, the best surgical staging technique this scenario is unknown. Objective To investigate sentinel biopsy (SLNB) dual-tracer mapping or targeted (TAD), which combines SLNB localization and retrieval clipped node. Design, Setting, Participants In multicenter retrospective cohort...
Abstract The molecular underpinnings of HER2-low and HER2-0 (IHC 0) breast tumors remain poorly defined. Using genomic findings from 1039 patients with HER2-negative metastatic cancer undergoing next-generation sequencing 7/2013-12/2020, we compare results between ( n = 487, 47%) 552, 53%). A significantly higher number ERBB2 alleles (median copy count: 2.05) are observed among compared to 1.79; P 2.36e-6), harboring a rate hemideletions (31.1% vs. 14.5%). No other alteration reaches...
Abstract Background: Data on the oncologic safety of omission axillary lymph node dissection (ALND) in positive (N+) patients who downstage to ypN0 with neoadjuvant chemotherapy (NAC) is sparse. Additionally, there no consensus which staging procedure should be used this setting, sentinel biopsy (SLNB) alone or combination localization and retrieval clipped node, also known as targeted (TAD). Whether reduction false negative rate observed TAD translates into a significant recurrence unknown....
In contrast to recurrence after initial diagnosis of stage I-III breast cancer [recurrent metastatic (rMBC)], de novo (dnMBC) represents a unique setting elucidate drivers in the absence treatment selection. We present genomic landscape dnMBC and association with overall survival (OS).Targeted DNA sequencing (OncoPanel) was prospectively performed on either primary or tumors from 926 patients (212 714 rMBC). Single-nucleotide variants, copy-number variations, tumor mutational burden (TMB)...
Abstract Capturing the full complexity of clinical experiences metastatic breast cancer (MBC) patients treated in a variety settings is needed to better understand this disease and develop new treatment modalities. Yet, challenges exist establish share large MBC dataset that integrates genomic, clinical, patient-reported data as it requires collecting information samples from many geographically dispersed institutions. We explored whether patient-partnered research approach uses online...
Breast cancer in young women (<40 years) is a rare and complex clinical psychosocial condition, which deserves multidisciplinary personalized approaches. In with hormone-receptor positive disease, 5 years of adjuvant tamoxifen, or without ovarian suppression/ablation, considered the standard endocrine therapy. The definitive role aromatase inhibitors has still to be elucidated: upcoming results Tamoxifen EXemestane Trial (TEXT) Suppression Ovarian Function (SOFT) trials will help...
A 76-year-old woman presented with symptoms suggestive of acute sinusitis. Previously, her breast carcinoma was treated right lumpectomy, adjuvant chemotherapy and radiotherapy. She remained free from recurrence for the following 8 years. After initial treatment antibiotics, local symptom worsened exophthalmos, eye blindness development an ulceration hard palate. MRI showed irregular enhancement nasal cavity extended to maxillary sinus ethmoidal lamina concomitant infiltration orbit skull...
The presence of a cortical erosion the posterior wall or an epidural mass is commonly considered contraindication to performing vertebral augmentation, considering perceived increased risk cement leak. Our aim was assess technical and clinical complications augmentation procedures performed for pain palliation and/or stabilization neoplastic lytic body lesions, with wall, often associated soft-tissue mass.In 48 patients, we retrospective assessment on 70 consecutive levels as demonstrated by...
The yield of comprehensive genomic profiling in recruiting patients to molecular-based trials designed for small subgroups has not been fully evaluated. We evaluated the likelihood enrollment a clinical trial that required identification specific change based on our institute-wide tumor profiling.Using from archived tissue samples derived with metastatic breast cancer treated between 2011 and 2017, we assessed impact systematic characterization an ongoing phase II (ClinicalTrials.gov...
489 Background: Oxaliplatin is widely used in metastatic colorectal cancer, but currently there are not valid predictors of response to this drug. In our recent retrospective clinical study we have shown a greater efficacy patients with cancer mutated (mt) K-RAS. We hypothesized that the mutational status K-RAS could influence expression ERCC1, one main mechanisms resistance. Methods: four cell lines cancer: two wild type (wt) (HCT-8 and HT-29) mt (SW620 SW480). evaluated sensitivity these...
Abstract The Metastatic Breast Cancer Project (MBCproject) is a research study that directly engages patients (pts) through social media and advocacy groups, empowers them to share samples, clinical data, experiences. goal create publicly available database of genomic, molecular, clinical, patient-reported data enable research. Working with pts advocates, website (MBCproject.org) was developed allows metastatic breast cancer (MBC) register. Registered are sent an online consent form asks for...
1022 Background: Genomic profiling of primary and recurrent metastatic breast cancer (rMBC) has revealed potential resistance mechanisms to therapy. In contrast, de novo stage IV (DNIV) represents an opportunity elucidate drivers in the absence treatment selection. Methods: Targeted NGS (Oncopanel, OP) using multiplexed copy number variation (CNV) mutation (mut) detection across full coding regions 300 genes selected intronic 35 was performed on either or samples collected patients (pts)...
Bisphosphonates are widely used both in the multidisciplinary management of bone metastases, especially osteolytic lesions from solid tumors or multiple myeloma, and osteoporosis. Aseptic osteonecrosis, jaw, is among well-known, although uncommon, side effects bisphospho nates. Osteonecrosis other bones has been very rarely reported with use bisphosphonates. We describe a rare case osteonecrosis distal femur associated bisphosphonates 74 years old female patient metastatic breast cancer.
First Page
A 60-year-old woman under treatment with letrozole for metastatic breast cancer underwent 18 F-FDG PET-CT restaging.A new widespread intense splenic FDG uptake without nodular lesions and multiple FDG-avid mediastinal abdominal nodes were observed.Based on these findings, a nodal transbronchial lung biopsy was performed.Histological results compatible sarcoidosis.The patient began steroid 6 weeks after showed normalisation of both uptake.In our case, has been useful in detecting rare case...
Abstract Background: Discordance in hormone receptor (HR) status between primary (p) tumors and metastatic (m) recurrences has been widely described. Loss of estrogen progesterone expression occurs ˜12% asynchronous recurrences, leading to triple-negative (TN) the metastasis. Genomic mechanisms driving HR loss its prognostic therapeutic implications have not fully elucidated. Methods: Targeted NGS (Oncopanel, OP) at Dana-Farber Cancer Institute using multiplexed copy number variation...
Abstract Background: Approximately 5-10% of newly diagnosed breast cancers (BC) are de novo MBC, which means that metastatic disease was identified at the time initial diagnosis. Patients with MBC underrepresented in currently available genomic studies. In The Cancer Genome Atlas (TCGA) dataset, only 15 out ˜980 BC patients can be classified as having MBC. objective this study is to analyze landscape and differences cohort early stage BC. To enhance our ability we utilized data from...